Golcadomide is a novel oral cereblon E3 ligase modulator (CELMoD) being developed by Bristol Myers Squibb for the treatment of lymphoma. Designed specifically for lymphoid malignancies, golcadomide preferentially distributes to lymphoid tissues and induces rapid degradation of the transcription factors Ikaros and Aiolos through cereblon engagement. This dual mechanism promotes direct lymphoma cell killing while enhancing immune-mediated antitumor activity. Earlier findings from the CC-220-DLBCL-001 study showed promising efficacy when combined with R-CHOP, leading to advancement into the Phase III (GOLSEEK-1) trial.

This analysis focuses on the golcadomide plus Pola-RCHP cohort in newly diagnosed aggressive B-cell lymphoma. Patients received six cycles of golcadomide with Pola-RCHP, with the primary objective of evaluating safety and determining whether addition of the CELMoD could enhance outcomes beyond current frontline standards. At data cutoff (DCU), 57 patients were treated with Golcadomide + Pola-RCHP (0.2 mg, n = 28; 0.4 mg, n = 29). Most patients had HR disease (86%) and DLBCL not otherwise specified histology (84%). Cell of origin (COO) was a germinal center B cell (GCB) in 47% of patients and non-GCB in 39% of patients by Hans algorithm. Forty-seven patients (83%) completed treatment and 52 (91%) entered the follow-up (f/u) period.

Safety Outcomes-

• Grade 3/4 Treatment-emergent adverse events (TEAEs) occurred in 95% of patients, most frequently neutropenia (86%; an on-target side effect of Golcadomide and anemia (39%). 

• Median relative dose intensity for Golcadomide and Pola-RCHP components was >95%.

KOL Insights-

“The combination of golcadomide and Pola-RCHP is particularly interesting because it integrates a next-generation cereblon modulator into an already active frontline regimen, potentially improving both immune activation and depth of response.”– Expert Opinion

“The high rates of complete metabolic response and MRD negativity observed with the 0.4 mg dose provide encouraging evidence that CELMoD-based strategies may help address unmet needs in high-risk DLBCL.”– Expert Opinion

Conclusion-

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30–40% of cases worldwide. Although frontline immunochemotherapy cures many patients, relapse remains a major challenge, particularly among those with high-risk clinical and biological features. Improving the depth and durability of remission in the first-line setting therefore remains a critical therapeutic goal.

Results from this Phase Ib study suggest that golcadomide may represent a promising new addition to frontline therapy for aggressive B-cell lymphomas. When combined with Pola-RCHP, golcadomide demonstrated encouraging complete metabolic response rates, high MRD-negativity rates, and durable progression-free outcomes, particularly at the 0.4 mg dose level. Importantly, these efficacy gains were achieved with a manageable and predictable safety profile and without compromising delivery of standard treatment. Collectively, these findings support continued clinical development of golcadomide-containing regimens and reinforce the potential role of CELMoD-based approaches in reshaping frontline treatment for high-risk DLBCL.